Mankind Pharma Limited

Mankind Pharma Limited - pharma in New Delhi, Delhi, India. FY 2026 financials & compliance.
CIN L74899DL1991PLC044843 Incorporated 03 July 1991 ROC Delhi HQ New Delhi, Delhi, India
Active Listed Public Limited Company pharma
Data last updated
Market Cap
₹1,00,601 Cr
MANKIND · NSE
Share Price
₹2,545.00
+4.49% today
Revenue
₹14,278 Cr
FY 2025-26 · +17.4% YoY
EBITDA
₹3,493 Cr
Margin 24.5%
Net Profit
₹2,014 Cr
FY 2025-26 · +12.2% YoY
P/E (TTM)
47.9x
P/B 6.3x
ROE
12.7%
ROCE 13.0%
Debt / Equity
0.48
Interest cover 24.7x

About Mankind Pharma Limited

Data last updated: 29 September 2026

Mankind Pharma Limited is a public limited company based in New Delhi, Delhi, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 03 July 1991, the company has been in operation for over 35 years.

Registered with ROC Delhi under CIN L74899DL1991PLC044843. Listed.

Capital: an authorised share capital of ₹421.51 Cr and a paid-up capital of ₹41.3 Cr. Formerly known as Mankind Pharma Private Limited. It is led by directors including Rajeev Juneja and Sheetal Arora.

Last AGM: 07 August 2025. Financial statements filed for year ended 31 March 2025. Office: 208 Okhla Industrial Estate Phase – Iii, New Delhi, Delhi, India – 110020.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹14,278 Cr, a growth of 16.96% compared to the previous year. The net worth stands at ₹16,300 Cr (up 13.73% YoY). Total assets are valued at ₹23,151 Cr (down 0.45% YoY).

The company has a workforce of approximately 19,928 employees as per the latest available data. Its group structure includes 22 subsidiaries.

The company is associated with 3 brands - Mediforce Healthcare, Manforce Condoms, Mankind Pharma. As per MCA filings, the company has open charges of ₹4,915 Cr and satisfied charges of ₹7,758.37 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website mankindpharma.com.

Company Details of Mankind Pharma Limited
CIN L74899DL1991PLC044843
Registration Number 044843
Incorporation Date 03 July 1991
ROC Delhi
Listing Status Listed
Company Status Active
Date of Last AGM 07 August 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Rajeev Juneja Managing Director Sheetal Arora Whole-Time Director Satish Kumar Sharma Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    mankindpharma.com
  • Social Media
  • Registered Address
    208 Okhla Industrial Estate Phase – Iii, New Delhi, Delhi, India – 110020
  • Industry
    Pharma, Drug Formulation & Development
Company report
Mankind Pharma Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Mankind Pharma Limited report

Financials, compliance, directors, charges, ownership and filings for Mankind Pharma Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Mankind Pharma Limited

Mankind Pharma Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74899DL1991PLC044843, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L74899DL1991PLC044843 Current
U74899DL1991PLC044843 Previous
U74899DL1991PTC044843 Previous

Associated Brands with Mankind Pharma Limited

Mankind Pharma Limited operates multiple associated brands including Mediforce Healthcare, Manforce Condoms, and Mankind Pharma. These brands represent Mankind Pharma Limited's diversified market presence and brand portfolio.

Brand Description Website
Mediforce Healthcare
Manufactures and distributes a range of medicines and healthcare products. mediforcehealthcare.com
Manforce Condoms
Condom manufacturing and sexual health resources in India. manforcecondoms.com
Mankind Pharma
Pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations mankindpharma.com

Competitors & Alternatives of Mankind Pharma Limited

Brands and companies operating in the same space as Mankind Pharma Limited include Jubilant Life Sciences, Akums, Nectar Lifesciences and 5 more.

Competitor Description Location Founded
Jubilant Life Sciences Jubilant Life Sciences Company offering a suite of R&D and manufacturing services for small molecules and generics Noida, India, India 1978
Akums Akums CDMO focusing on spectrum of dosage forms and therapeutic segments Delhi, India, India 2004
Nectar Lifesciences Nectar Lifesciences Cephalosporin APIs and generic formulations are manufactured. Chandigarh, India, India 1995
Windlas Windlas Biopharma regulatory affairs, quality control, and strategy services are provided. Gurugram, India, India 2001
Unither Unither Contract development and manufacturing organization for proprietary and generic drugs Paris, France, France 1993
Recipharm Recipharm Pharmaceutical development and manufacturing services are offered contractually. Jordbro, Sweden, Sweden 1995
CoreRx CoreRx CDMO with a focus on early phase drug product development Clearwater, United States, United States 2006
MedPharm MedPharm Topical and inhaled drug delivery formulations are developed and manufactured. Guildford, United Kingdom, United Kingdom 1998

Business Activity of Mankind Pharma Limited

Mankind Pharma Limited is engaged in principal business activities including trade and manufacturing, with detailed activities including wholesale trading, chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
G Trade G1 Wholesale Trading Locked
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Mankind Pharma Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Mankind Pharma Limited

Mankind Pharma Limited is audited by S.R. Batliboi & CO. LLP for the financial year 2025. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
S.R. Batliboi & CO. LLP Locked Locked Locked
Premium access

Complete auditor history for Mankind Pharma Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Mankind Pharma Limited

Mankind Pharma Limited is currently managed by 8 directors, with 18 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Rajeev Juneja
Also directs: Appian Associates Infrastructure Private Limited, Pavi Buildwell Private Limited, Luxor Metaltec India Pvt Ltd and 5 more
Managing Director 22 Dec 1992 33 Years 9 Months Current
Sheetal Arora
Also directs: Pavi Buildwell Private Limited, Kindcare Foundation, Appian Projects Llp and 5 more
Whole-Time Director 21 Sep 2007 19 Years 0 Months Current
Bharat Anand
Also directs: Kindcare Foundation, Bharat Serums And Vaccines Limited, Khaitan & Co Llp and 5 more
Director 31 Aug 2018 8 Years 0 Months Current
Tilokchand Punamchand Ostwal
Also directs: T.P.Ostwal & Associates Llp, Polycab India Limited, Lambda Therapeutic Research Limited and 4 more
Director 01 Jan 2020 6 Years 8 Months Current
Vijaya Sampath
Also directs: Ingersoll-Rand (India) Limited, Craftsman Automation Limited, Va Tech Wabag Limited and 4 more
Director 01 Aug 2022 4 Years 1 Months Current
Vivek Kalra
Also directs: Kindcare Foundation, Salsette Advisors Llp, B N B S Cements And Products Pvt Ltd
Director 01 Aug 2022 4 Years 1 Months Current
Showing 6 of 8 current directors. View all directors

Financials of Mankind Pharma Limited FY 2025-26 filings available

Mankind Pharma Limited reported revenue of ₹14,278 Cr (up 16.96% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹14,278 Cr
+17.0% YoY
EBITDA
₹3,493 Cr
+15.6% YoY
Profit After Tax
₹2,014 Cr
+12.2% YoY
Net Worth
₹16,300 Cr
+13.7% YoY
Total Assets
₹23,151 Cr
-0.4% YoY
Total Debt
₹6,312 Cr
-25.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue14,27812,20710,2608,7497,7826,2145,865
Revenue growth+17.4%+18.6%+13.1%+18.2%+26.9%+3.1%+61.1%
EBITDA3,4933,0202,5151,9021,9911,6491,438
EBITDA margin+24.5%+24.7%+24.5%+21.7%+25.6%+26.5%+24.5%
Profit before tax2,3332,5212,3991,6711,9751,6921,438
Net profit2,0141,7961,8071,2531,3691,217998
Net profit margin+14.1%+14.7%+17.6%+14.3%+17.6%+19.6%+17.0%
EPS (₹)1,913.0648.2547.7532.0035.7831.5925.72
Balance sheet
Total assets23,15123,2559,9297,9177,2905,1853,884
Net worth16,30014,3329,3637,4356,1554,7223,485
Total debt6,3128,511207170873241131
Cash & bank483554708453406701420
Net working capital2,3292,6052,3651,5311,7301,426976
Cash flow
Cash from operations3,1212,4132,1521,8139201,1371,070
Cash from investing(181)(12,624)(2,081)(1,052)(1,369)(1,222)(436)
Cash from financing(2,953)10,2335.27(740)605(7.81)(531)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue4,0313,4433,5673,6973,5703,0793,1993,061
Revenue growth (YoY)+12.9%+11.8%+11.5%+20.8%+24.5%+27.1%+22.7%+13.1%
Other income48.9411775.9694.1983.0525487.09112
EBITDA1,056907813921847679816845
EBITDA margin+26.2%+26.3%+22.8%+24.9%+23.7%+22.0%+25.5%+27.6%
Depreciation226223223222219231187100
Interest1101421571701711912217.10
Profit before tax769659509624540511495849
Tax19599.7595.1210495.8786.44110190
Net profit574559414520445425385659
EPS (₹)13.7413.419.8912.3810.6010.189.4416.28
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue10,4219,5078,6298,1277,4865,5304,794
Revenue growth+5.1%+11.3%-1.0%+13.8%+36.1%+16.9%+13.7%
EBITDA2,9802,4252,2671,6981,8381,3791,244
EBITDA margin+28.6%+25.5%+26.3%+20.9%+24.6%+24.9%+26.0%
Profit before tax2,3152,2082,2891,5631,8711,4401,265
Net profit2,1251,6051,7701,2191,3271,054940
Net profit margin+20.4%+16.9%+20.5%+15.0%+17.7%+19.1%+19.6%
EPS (₹)49.3643.2946.8331.1634.6827.0723.92
Balance sheet
Total assets22,19421,8379,8517,8987,3174,8983,715
Net worth16,39714,3239,7037,7846,5404,7343,651
Total debt5,5717,38323.504.696881012.56
Cash & bank159306484155139477198
Net working capital7035581,7911,0381,3611,212739
Cash flow
Cash from operations2,7522,3501,7361,7998211,022960
Cash from investing(388)(12,178)(1,665)(1,041)(1,360)(1,127)(396)
Cash from financing(2,477)9,816(4.73)(710)57988.87(559)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,9642,5822,6332,6092,5702,1192,4142,544
Revenue growth (YoY)+15.3%+21.8%+9.0%+2.5%+6.5%+5.6%+9.3%+12.6%
Other income33.9612756.5277.6765.2122070.37139
Total expenses2,0351,6861,9381,9161,8851,7781,6681,781
EBITDA929896695693685342746763
EBITDA margin+31.3%+34.7%+26.4%+26.6%+26.7%+16.1%+30.9%+30.0%
Depreciation11110910899.0310511591.1190.33
Interest94.951251381471491622002.61
Profit before tax757788505525496284525810
Tax19874.4056.4165.7380.9046.29113165

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 29 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue4,0313,4433,5673,6973,5703,0793,1993,061
Revenue growth (YoY)+12.9%+11.8%+11.5%+20.8%+24.5%+27.1%+22.7%+13.1%
Other income48.9411775.9694.1983.0525487.09112
EBITDA1,056907813921847679816845
EBITDA margin+26.2%+26.3%+22.8%+24.9%+23.7%+22.0%+25.5%+27.6%
Depreciation226223223222219231187100
Interest1101421571701711912217.10
Profit before tax769659509624540511495849
Tax19599.7595.1210495.8786.44110190
Net profit574559414520445425385659
EPS (₹)13.7413.419.8912.3810.6010.189.4416.28
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue14,27812,20710,2608,7497,7826,2145,865
Revenue growth+17.4%+18.6%+13.1%+18.2%+26.9%+3.1%+61.1%
Other income370554296141210183122
Total expenses10,7859,1877,7456,8485,7914,5654,427
Employee cost3,1842,6922,2611,9181,6211,4161,336
EBITDA3,4933,0202,5151,9021,9911,6491,438
EBITDA margin+24.5%+24.7%+24.5%+21.7%+25.6%+26.5%+24.5%
Depreciation88662137832616711999.06
Interest64443234.2445.7659.8021.1623.24
Profit before tax2,3332,5212,3991,6711,9751,6921,438
Tax395510457362522399382
Net profit2,0141,7961,8071,2531,3691,217998
Net profit margin+14.1%+14.7%+17.6%+14.3%+17.6%+19.6%+17.0%
EPS (₹)1,913.0648.2547.7532.0035.7831.5925.72
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital41.2841.2640.0640.0640.0640.0640.06
Reserves & surplus16,25914,2919,3237,3956,1154,6823,445
Shareholders' funds (net worth)16,30014,3329,3637,4356,1554,7223,485
Minority interest261236213188161141186
Secured loans5,7656,026196163804224114
Unsecured loans5472,48511.137.7368.7517.1416.68
Total debt6,3128,511207170873241131
Total liabilities23,15123,2559,9297,9177,2905,1853,884
Assets
Gross block21,37720,9175,9155,2394,2522,1661,993
Net block18,62019,0054,5454,2513,5881,6641,600
Capital work in progress1,128826282550701372317
Investments1,9852,0422,5681,3461,1091,512829
Inventories2,1442,0941,5531,4981,7601,184899
Sundry debtors1,7301,538848576388331531
Cash & bank balances483554708453406701420
Loans & advances1,0601,1111,200724978386307
Total current assets5,4175,2974,3103,2523,5322,6002,157
Total current liabilities3,0882,6921,9451,7211,8031,1751,181
Net working capital2,3292,6052,3651,5311,7301,426976
Total assets23,15123,2559,9297,9177,2905,1853,884
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash404382305283127220116
Net cash from operating activities3,1212,4132,1521,8139201,1371,070
Net cash from investing activities(181)(12,624)(2,081)(1,052)(1,369)(1,222)(436)
Net cash from financing activities(2,953)10,2335.27(740)605(7.81)(531)
Net change in cash(12.19)21.8777.1921.76156(92.40)103
Closing cash483554708453406701420
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+17.0%+19.0%+17.3%+12.4%+25.2%+6.0%+75.9%
EBITDA growth+15.6%+20.1%+32.2%-4.5%+20.7%+14.7%+145.5%
PBT growth-7.5%+5.1%+43.5%-15.4%+16.7%+17.7%+131.5%
Net income growth+12.2%-0.6%+44.2%-8.5%+12.5%+22.0%+127.1%
Revenue CAGR (3Y)+17.7%+16.2%+18.2%+14.3%+32.7%--
EBITDA CAGR (3Y)+22.5%+14.9%+15.1%+9.8%+50.3%--
Profitability & leverage
Net income margin+13.6%+16.5%+18.9%+15.0%+18.7%+20.8%+18.0%
Return on capital employed+13.0%+18.0%+27.9%+23.1%+33.4%+39.2%+39.5%
Return on net worth+12.7%+17.0%+23.1%+19.3%+26.7%+31.5%+30.3%
Debt / equity0.480.370.020.080.100.050.04
Long-term debt / equity0.280.240.000.010.010.010.01
Interest cover24.7218.001.602.903.281.381.74
Efficiency & per share
Fixed asset turnover0.680.911.841.842.432.992.94
Inventory turnover6.746.696.725.375.295.976.52
Debtors turnover8.7410.2314.4018.1421.6514.4211.04
EPS (₹)1,913.0648.2547.7532.0035.7831.5925.72
Dividend per share (₹)1.000.000.000.000.007.600.00
Book value per share (₹)16,301.46347.37233.73185.61153.65117.8887.00
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,9642,5822,6332,6092,5702,1192,4142,544
Revenue growth (YoY)+15.3%+21.8%+9.0%+2.5%+6.5%+5.6%+9.3%+12.6%
Other income33.9612756.5277.6765.2122070.37139
Total expenses2,0351,6861,9381,9161,8851,7781,6681,781
EBITDA929896695693685342746763
EBITDA margin+31.3%+34.7%+26.4%+26.6%+26.7%+16.1%+30.9%+30.0%
Depreciation11110910899.0310511591.1190.33
Interest94.951251381471491622002.61
Profit before tax757788505525496284525810
Tax19874.4056.4165.7380.9046.29113165
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue10,4219,5078,6298,1277,4865,5304,794
Revenue growth+5.1%+11.3%-1.0%+13.8%+36.1%+16.9%+13.7%
Other income32655537416320414893.85
Total expenses7,4417,0826,3626,4295,6484,1513,550
Employee cost2,3672,1491,9211,7011,4631,106991
EBITDA2,9802,4252,2671,6981,8381,3791,244
EBITDA margin+28.6%+25.5%+26.3%+20.9%+24.6%+24.9%+26.0%
Depreciation42939533527012378.1961.77
Interest56237816.9328.2347.548.2311.10
Profit before tax2,3152,2082,2891,5631,8711,4401,265
Tax277422413315482356307
Net profit2,1251,6051,7701,2191,3271,054940
Net profit margin+20.4%+16.9%+20.5%+15.0%+17.7%+19.1%+19.6%
EPS (₹)49.3643.2946.8331.1634.6827.0723.92
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital41.2841.2640.0640.0640.0640.0640.06
Reserves & surplus16,35614,2819,6637,7446,5004,6943,611
Shareholders' funds (net worth)16,39714,3239,7037,7846,5404,7343,651
Secured loans5,4885,44414.930.0062495.000.00
Unsecured loans82.521,9398.574.6964.235.852.56
Total debt5,5717,38323.504.696881012.56
Total liabilities22,19421,8379,8517,8987,3174,8983,715
Assets
Gross block5,8915,6584,5783,7763,2921,2271,117
Net block3,9264,0763,5523,1422,927987945
Capital work in progress420207209495387166148
Investments16,52316,6834,2153,1022,5262,3971,784
Inventories1,0881,0981,1261,0321,267827533
Sundry debtors1,164909769493471369419
Cash & bank balances159306484155139477198
Loans & advances7248491,0117751,071521404
Total current assets3,1353,1623,3902,4552,9472,1941,554
Total current liabilities2,4322,6041,5991,4181,586982816
Net working capital7035581,7911,0381,3611,212739
Total assets22,19421,8379,8517,8987,3174,8983,715
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash20121214586.1746.3677.5072.48
Net cash from operating activities2,7522,3501,7361,7998211,022960
Net cash from investing activities(388)(12,178)(1,665)(1,041)(1,360)(1,127)(396)
Net cash from financing activities(2,477)9,816(4.73)(710)57988.87(559)
Net change in cash(113)(10.96)66.1647.9639.81(15.96)5.02
Closing cash159306484155139477198
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+9.6%+10.2%+6.2%+8.6%+35.4%+15.3%+25.2%
EBITDA growth+22.9%+7.0%+33.5%-7.7%+33.4%+10.8%+76.5%
PBT growth+4.9%-3.5%+46.5%-16.5%+29.9%+13.9%+83.0%
Net income growth+32.4%-9.3%+45.2%-8.2%+25.9%+12.2%+82.7%
Revenue CAGR (3Y)+8.6%+8.3%+16.0%+19.2%+25.0%+12.2%+11.1%
EBITDA CAGR (3Y)+20.6%+9.7%+18.0%+10.9%+37.7%+21.0%+21.1%
Profitability & leverage
Net income margin+19.6%+18.8%+21.7%+15.4%+18.6%+19.6%+20.0%
Return on capital employed+13.1%+16.3%+23.4%+20.9%+31.4%+33.6%+36.4%
Return on net worth+13.3%+14.9%+20.3%+17.4%+24.7%+25.9%+28.5%
Debt / equity0.420.310.000.050.070.010.03
Long-term debt / equity0.250.210.000.000.000.000.00
Interest cover22.0518.590.881.982.770.630.94
Efficiency & per share
Fixed asset turnover1.801.862.072.303.314.724.77
Inventory turnover9.548.558.007.077.158.139.45
Debtors turnover10.0611.3313.6816.8717.8314.0417.19
EPS (₹)49.3643.2946.8331.1634.6827.0723.92
Dividend per share (₹)1.000.000.000.000.000.007.55
Book value per share (₹)397.21347.13242.21194.31163.27118.1891.15
Want more history and ratios?
You're viewing the latest exchange-filed financials for Mankind Pharma Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Mankind Pharma Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 72.60%, foreign institutional investors hold 9.40%, domestic institutional investors hold 15.40%, retail and other public shareholders hold 2.60% of Mankind Pharma Limited.

Promoters: 72.60%DII (Domestic Institutional): 15.40%FII (Foreign Institutional): 9.40%Retail & Others: 2.60%
Jun 2026
QUARTER
72.60% Promoters
15.40% DII (Domestic Institutional)
9.40% FII (Foreign Institutional)
2.60% Retail & Others
Promoter holding - history
Now 72.60% · Jun 2026High 72.70% · Sep 2025Low 72.60% · Jun 2026
71%71.8%72.5%73.3%74%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 72.70%Dec 2025: 72.70%Mar 2026: 72.70%Jun 2026: 72.60%72.70%72.60%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters72.60%72.70%72.70%72.70%
Public27.40%27.30%27.30%27.30%

Group Structure of Mankind Pharma Limited

Mankind Pharma Limited has 22 subsidiary companies and 2 associated companies. This group structure data is as of FY 2024. The corporate group structure reflects Mankind Pharma Limited's business expansion strategy and organizational complexity.

22
Subsidiary companies
2
Associated companies
Key Subsidiaries
Company Name CIN Shares Held
Qualitek Starch Private Limited U15134HP2019PTC007684 -
Mankind Medicare Private Limited U21002DL2023PTC419826 -
Appian Properties Private Limited U24100DL2017PTC321898 -
Mankind Life Sciences Private Limited U24100DL2020PTC369904 -
Mankind Consumer Healthcare Private Limited U24230DL2021PTC388536 -
Pharmaforce Excipients Private Limited U24230HP2019PTC007703 -

Showing major subsidiaries. Total: 22.

Charges & Borrowings of Mankind Pharma Limited

Open charges
₹4,915 Cr
Satisfied charges
₹7,758.37 Cr
Breakdown by lending institutions
Others₹4,060.00 Cr
Hdfc Bank Limited₹355.00 Cr
State Bank of India₹300.00 Cr
Citi Bank N.A.₹200.00 Cr
Latest charge details
DateLenderAmountStatus
14 Nov 2024 Others ₹1,250 Cr Open
14 Nov 2024 Others ₹2,500 Cr Open
14 Oct 2024 State Bank of India ₹300 Cr Open
26 Dec 2023 Others ₹200 Cr Open
30 Mar 2021 Others ₹110 Cr Open

Total charge records: 38 View all charges

Employees and EPFO Compliance at Mankind Pharma Limited

Mankind Pharma Limited has a workforce of 19,928 employees as of Oct 10, 2025.

Employee count
19,928
Active EPFO establishments
3
Employee growth
0.06%
Premium access

Employee and EPFO history for Mankind Pharma Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Mankind Pharma Limited

Premium access

GST registrations and filing compliance for Mankind Pharma Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Mankind Pharma Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Mankind Pharma Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Mankind Pharma Limited

Premium access

MSME payment history for Mankind Pharma Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Mankind Pharma Limited

Premium access

Corporate group structure for Mankind Pharma Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Mankind Pharma Limited

Premium access

MCA filings and documents for Mankind Pharma Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Mankind Pharma Limited

Charges
29 Jun 2026
A charge with Others of Rs. 110.00 Cr registered on 30 Mar 2021 with Charge ID 100439267 was modified on 29 Jun 2026.
Charges
15 Jun 2026
A charge registered on 07 Sep 2018 via Charge ID 100211107 with Hdfc Bank Limited was fully satisfied on 15 Jun 2026.
Charges
20 May 2026
A charge registered on 14 Nov 2024 via Charge ID 101005947 with Others was fully satisfied on 20 May 2026.
Charges
18 Feb 2026
A charge registered on 24 Nov 2025 via Charge ID 101202514 with Citi Bank N.A. was fully satisfied on 18 Feb 2026.
Charges
09 Dec 2025
A charge with Hdfc Bank Limited of Rs. 355.00 Cr registered on 11 Dec 2020 with Charge ID 100401490 was modified on 09 Dec 2025.
Charges
24 Nov 2025
A charge with Citi Bank N.A. amounted to Rs. 106.00 Cr with Charge ID 101202514 was registered on 24 Nov 2025.

Recent News on Mankind Pharma Limited

Frequently Asked Questions about Mankind Pharma Limited

Mankind Pharma Limited is an active public limited company in the pharma sector based in New Delhi, Delhi, India. It was incorporated on 03 July 1991 (35+ years old) and is registered under CIN L74899DL1991PLC044843. The company has 19,928 employees.

Mankind Pharma Limited reported revenue of ₹14,278 Cr for FY 2025-26 (up 16.96% YoY) based on consolidated financials.

The current directors of Mankind Pharma Limited are:

The primary industry of Mankind Pharma Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes, Mankind Pharma Limited is a listed company.

Mankind Pharma Limited can be reached at the registered office: 208 Okhla Industrial Estate Phase – Iii, New Delhi, Delhi, India – 110020, or through the website mankindpharma.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available